Ligand establishes new business units
Ligand Pharmaceuticals, from San Diego, has advanced the structure of its operations by establishing separate therapeutically focused business units for its pain and oncology products.
Ligand Pharmaceuticals, from San Diego, has advanced the structure of its operations by establishing separate therapeutically focused business units for its pain and oncology products.
Patrick Shea, formerly vice president of marketing, has been promoted to vice president of marketing and sales for the oncology products unit. Matthew Witte, formerly vice president of sales, has been promoted to vice president of marketing and sales for the pain products unit. The company's currently marketed pain product is Avinza (morphine sulfate extended-release capsules). Targretin (bexarotene) capsules and gel, Ontak (denileukin diftitox), and Panretin gel comprise the oncology products unit.
'These business units should significantly enhance our ability to simultaneously design and execute improved Avinza commercial results and to design and execute plans to capitalise on significant oncology opportunities such as Targretin in non-small cell lung cancer and Ontak in B-cell non-Hodgkin's lymphoma,' said William Pettit, Ligand's senior vice president, human resources and administration. 'The focused expertise of these two professionals as heads of our key business franchises and their teams will strengthen our ability to focus and execute on our major commercial business goals and objectives.'